A new study has found that a pill called Daraxonrasib
is helping people with advanced pancreatic cancer
live longer.
Researchers at the University of California, Los Angeles,
say the drug blocks a mutated protein that
fuels tumor growth in more than 90 percent
of pancreatic cancer cases.
Dr. Zev Wainberg, who led the study,
says the daily pills nearly double survival time:
a median of 13.2 months
and with fewer side effects
compared to additional chemotherapy.
The findings are in the New England Journal of Medicine
and were presented Sunday at the American Society
for Clinical Oncology meeting in Chicago.
I’m Donna Warder.